Search form
Search
contact us
Navigation
home
boards
Jobs
job ratings
cp wire
medtech news
pharmagather
catering
advertise
whistleblower info
pharmaceutical fraud
medical device | DME fraud
clinical lab fraud
False Claims Act
Legal Help
login/register
You are here
Home
» In wake of Eli Lilly setback, Merck KGaA’s leading BTK drug for autoimmune disease clears PhIIb hurdle
In wake of Eli Lilly setback, Merck KGaA’s leading BTK drug for autoimmune disease clears PhIIb hurdle
In wake of Eli Lilly setback, Merck KGaA’s leading BTK drug for autoimmune disease clears PhIIb hurdle
Submitted by
admin
on March 9, 2018 - 10:48am
Source:
Endpoints
News Tags:
Eli Lilly
Merck KGaA
Btk inhibitors
autoimmune disease
evobrutinib
Headline:
In wake of Eli Lilly setback, Merck KGaA’s leading BTK drug for autoimmune disease clears PhIIb hurdle
Do Not Allow Advertisers to Use My Personal information
